Pegylated Octadecyl Lithocholate Micelles for Targeted Rapamycin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for colorectal cancer, such as surgery, chemotherapy, and targeted therapies, face challenges including severe side effects, limited drug accumulation in tumors, and high systemic toxicity, particularly with drugs like rapamycin, which has poor water solubility and unpredictable bioavailability.
Innovation Solution
Development of pegylated octadecyl lithocholate micelles labeled with a peptide ligand for colorectal neoplasia that encapsulate rapamycin, utilizing a block co-polymer structure with a hydrophobic bile acid core, a hydrophilic polymer shell, and a targeting peptide for specific delivery to colorectal cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If rapamycin is administered parenterally to treat colorectal cancer, then tumor accumulation is improved, but water solubility is poor leading to limited delivery
Solution Approach 1:
The patent uses a composite micelle structure composed of hydrophobic bile acid (octadecyl lithocholate) and hydrophilic polymer (PEG) to encapsulate rapamycin. This composite material combines the solubility benefits of both hydrophobic and hydrophilic components, enabling the hydrophobic rapamycin to be delivered effectively in aqueous environments while maintaining tumor accumulation capability.
Solution Approach 2:
The micelle structure employs a flexible PEG shell surrounding a hydrophobic core. This flexible shell structure allows the micelle to stabilize the hydrophobic drug in aqueous environments while maintaining structural integrity for targeted delivery to tumors.
2Reliability
If conventional chemotherapy is used to treat colorectal cancer, then tumor treatment is achieved, but severe side effects occur including diarrhea and neuropathy
Solution Approach 1:
The patent segments the drug delivery system into a targeted micelle structure that separates the drug delivery function from systemic distribution. The micelle selectively accumulates in tumor tissue through EPR effect and peptide targeting, leaving healthy tissues unaffected, thereby reducing side effects while maintaining treatment effectiveness.
Solution Approach 2:
The micelle acts as an intermediary carrier between the hydrophobic drug and the aqueous biological environment. This intermediary structure protects the drug from premature degradation and prevents direct contact with healthy tissues, reducing harmful side effects while enabling effective tumor treatment.
3Quantity of substance
If targeted therapy with monoclonal antibodies is used, then specific drug delivery is improved, but size limitations reduce drug accumulation within tumors
Solution Approach 1:
The patent uses a smaller micelle structure that copies the targeting functionality of large monoclonal antibodies but with reduced size constraints. The micelle incorporates peptide ligands that mimic antibody targeting capabilities while maintaining a size suitable for effective tumor penetration and accumulation.
4Reliability
If free rapamycin is used to treat colorectal cancer, then mTOR inhibition is achieved, but high systemic toxicity occurs
Solution Approach 1:
The patent segments the distribution of rapamycin from systemic circulation to targeted tumor accumulation through micelle encapsulation. This segmentation concentrates the drug effect in the tumor while minimizing exposure to healthy organs, reducing systemic toxicity while maintaining mTOR inhibition efficacy.
Solution Approach 2:
The micelle serves as an intermediary that controls the release and distribution of rapamycin. This intermediary structure ensures the drug reaches the tumor site through passive and active targeting mechanisms before releasing the active compound, thereby maintaining efficacy while reducing systemic toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted micelle delivery system enhances tumor accumulation, reduces systemic toxicity, and achieves sustained release of rapamycin, leading to significant adenoma regression with minimal adverse effects, comparable to free rapamycin therapy but with reduced toxicity.
Implementation Method 1
These agents form spontaneously by self-assembly and degrade within tumor cells
Implementation Method 2
hydrophobic component A is a bile acid, hydrophilic component B is a polymer
Data Source
AI summary
The present invention relates to micelle drug carriers and methods of using the micelles to deliver drugs to target cells. The micelles are useful, for example, for carrying and targeting drugs for the treatment of cancer to cancer cells. As one example, the disclosure provides pegylated octadecyl lithocholate micelles that are labeled with a peptide ligand for colorectal neo-plasia and that carry the small molecule mTOR inhibitor rapamycin to colorectal cancer cells.